Philips upgrades patient monitoring software
October 11, 2016
Philips has announced the latest version of its IntelliVue Guardian software, designed to help clinicians in the early recognition of subtle signs of patient deterioration in the general care ward.
This software can notify caregivers to early signs of potential degradation, which can help reduce costly complications, unplanned transfers back to the intensive care unit and longer lengths of stay in the hospital.
It is configurable to most institutions' early warning scoring protocols, and includes features such as compatibility with the SureSigns VS4 spot check monitors and the IntelliVue MP5SC monitor.
The software provides caregivers in general care wards with direct access to an automated scoring system that can be based on individual hospital policy. It can help improve patient care, financial outcomes and clinician workflow by facilitating early intervention.
Having automated tools that provide a comprehensive view into a patient's condition helps enhance workflow efficiencies, simplify the medical documentation process and better use limited staff resources.
It can also be used with the Philips wearable biosensor, a medical-grade, self-adhesive, single patient-use wireless device worn discreetly on the chest. The biosensor automatically and continuously measures heart rate, respiratory rate and posture, and detects falls. These data can be transmitted to the Guardian software, which analyses the combined trends of the measurements over a configurable period of time and notifies the appropriate caregiver or clinician when pre-set limits are exceeded.
This provides caregivers with peace of mind that their patients are being monitored frequently for signs of deterioration between spot checks while they are attending to other tasks. The wireless biosensor provides patients with freedom of mobility.
"Studies have shown that signs of clinical instability typically occur six to eight hours prior to a potential deterioration and that the most common predictors of this deterioration are changes in respiratory and heart rate," said Carla Kriwet, the Dutch company’s CEO for patient care and monitoring. "The IntelliVue Guardian software – in tandem with the wearable biosensor –allows for the continuous and automatic collection and transmission of information to help caregivers recognise these signs of instability earlier, before a deterioration can occur."
The latest release supporting the biosensor is available from this month to countries requiring the CE Mark. This software and the biosensor are pending FDA 510(k) clearance and are not yet for sale in the USA.
• Philips has announced a partnership with the World Heart Federation to help people better manage their heart health. Aligned with the WHF's “power your life” campaign, Philips aims to encourage people to take personal responsibility for leading heart-healthy lives and raise awareness about cardiovascular disease.